anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Integrated Management of Childhood Illness (IMCI) is a child health strategy in developing countries with a goal of improving the treatment of illnesses at first-level health facilities through the use of clinical practice guidelines. The World Health Organization (WHO) recommends implementing the guidelines with an 11-day training course. There is a concern that health workers might not master all aspects of the guidelines and that health worker performance may deteriorate over time. In 1999, Benin (in West Africa) was planning to implement IMCI. In response to concerns about how well health workers would follow IMCI guidelines, interventions were designed to support health workers after IMCI training: 1) regular supervision of health workers; 2) supervision of supervisors; 3) job aids; and 4) non-financial incentives for health workers. These interventions were intended to be used together. The objective of this study was to determine the effectiveness and cost-effectiveness of the package of interventions to support IMCI-trained health workers in Benin.
During fetal development the developing babe pushes against the uterine wall, often kicking and punching the unfortunate mother, especially during the last few months of pregnancy. The striking out against the resistance of the uterine wall causes joint compression in the arms, legs, and spine and that sensory feedback triggers bone growth. Unfortunately in the premature infant they are robbed of that exercise opportunity and are either splayed out in an incubator trying to copy with movement against gravity or swaddled so that movement isn't really an option. As a result bone density loss occurs in essentially all premature infants and osteopenia or significant loss can be an issue.

Between 1995 and 2008 there was a good deal of work done on identifying the importance of exercise and movement for premature infants. Moyer-Mileur was the leading researcher in the USA who demonstrated that simple exercise programs could prevent or decrease bone density loss. Although there is a shortage of trained therapists to provide these exercises safely they became a fairly common practice by 2010. At about that time the neonatologists at the Asante facility asked to incorporate the exercises into the NICU therapy program and after appropriate training the exercises began.

The Asante NICU is highly developmentally oriented. Infants grow 150 million brain cells an hour during the last few months of pregnancy. Any of the multiple stressors of prematurity can create cortisol and affect that brain growth. For that reason therapists became concerned with the joint compression exercises. While they were good for bone and muscle health the exercises were not always welcomed by the infant. Even the most gentle compassionate therapist is not always welcome if the infant just wants to sleep or be left alone. Therapists sought a system that could provide the needed exercise but in a manner more developmentally appropriate. It took two years of experimenting with different types of materials and different strengths of elasticity before the Prepod design finally evolved. Then the obvious hypothesis was - Will the Prepod be as effective in decreasing bone density loss as the traditional therapy exercises?? After multiple issues replacing originally planned DEXA measurements with safer UTS measurements, the first subjects were enrolled in 2013. Unfortunately in 2015 an issue with the ultrasound machine was identified; the anti-theft anklets the infants wore emitted signals that had corrupted the data. The study needed to be restarted in 2015, removing the anklets prior to measurement. It then proceeded without incident, with expected completion late 2018. At the IRB (Institutional Review Board) review winter of 2017 the overseeing group concluded that the data for length of stay was so compelling that continuing the study wasn't likely to change anything and basically amounted to withholding care from the traditional exercise infants. They ordered early closure of the study, despite the small number of study participants.
Space-related stressors such as microgravity are associated with cellular and molecular alterations of the immune and inflammatory homeostasis that have been linked to the disorders that astronauts suffer from during their missions. Most of the research of the past 30 years has consistently established that innate adaptive immune cells represent a target of microgravity, which leads to their defective or dysfunctional activation, as well as to an altered ability to produce soluble mediators-e.g., cytokines/chemokines and bioactive lipids-that altogether control tissue homeostasis. Bioactive lipids include a vast array of endogenous molecules of immune origin that control the induction, intensity and outcome of the inflammatory events. However, none of the papers published so far focus on a newly characterized class of lipid mediators called specialized pro-resolving mediators (SPMs), which orchestrate the "resolution of inflammation"-i.e., the active control and confinement of the inflammatory torrent mostly driven by eicosanoids. SPMs are emerging as crucial players in those processes that avoid acute inflammation to degenerate into a chronic event. Given that SPMs, along with their metabolism and signaling, are being increasingly linked to many inflammatory disorders, their study seems of the outmost importance in the research of pathological processes involved in space-related diseases, also with the perspective of developing therapeutic countermeasures. Here, we show that microgravity, simulated in the rotary cell culture system (RCCS) developed by NASA, rearranges SPM receptors both at the gene and protein level, in human monocytes but not in lymphocytes. Moreover, RCCS treatment reduces the biosynthesis of a prominent SPM like resolvin (Rv) D1. These findings strongly suggest that not only microgravity can impair the functioning of immune cells at the level of bioactive lipids directly involved in proper inflammation, but it does so in a cell-specific manner, possibly perturbing immune homeostasis with monocytes being primary targets.
The invention discloses a hanyu asthma relieving liquid for curing asthma and its manufacturing method. It selects living mud eel about 2500g, and adds 6750g-8250g of wine and immerse for 15-25 days, acquires the filtered liquid, another five kinds of medicines are crashed into raw powder, adds in 3380-4140g wines according to the whole weigh of the raw powder, and immerse them for 72 hours, and carries on disacolation slowly with speed of 1-3mL per minute, filters and gathers filtered liquid. The above mentioned two kinds of filtered liquid are mixed together, and placed for ten days, then filters them again, and places them for 15 days, then carries on filter repeatedly, the product can be produced. The medicine has functions of lung moistening and asthma relieving. The invention has no toxin and side effects, the curative rate can reach to 92.9%. The invention has a short curative period, prominent curative effect, and has no toxin and side effects.
Use of raloxifene hydrochloride is associated with the reduction of the risk of invasive breast cancer in postmenopausal women. Raloxifene hydrochloride has not been shown to reduce the risk of noninvasive breast cancer. When considering treatment, physicians need to discuss the potential benefits and risks of raloxifene hydrochloride treatment with the patient.

Raloxifene hydrochloride is not indicated for the treatment of invasive breast cancer or reduction of the risk of recurrence.

Patients should have breast exams and mammograms before starting raloxifene hydrochloride and should continue regular breast exams and mammograms in keeping with good medical practice after beginning treatment with raloxifene hydrochloride.

Rev: 05/2020
Diagnostic, radiotherapy, and chemotherapy methods which may be used in conjunction with gene therapy techniques, and the use of certain compounds in performing these methods. The methods are applicable to populations of cells into which a foreign gene has been transferred, which foreign gene expresses a protein which preferably is not naturally occuring within the cells. A  compound is selected which will interact selectively with the protein expressed by the foreign gene to produce a product which is trapped within the cells, is cytotoxix or cytostatic to the cells, or both, depending upon whether the compound is being used for diagnostic purposes or for radiotherapy or chemotherapy purposes. In the case of diagnostic applications, trapping of the product, which is labelled, permits the product to accumulate in those of the cells in which the protein has been expressed by the foreign gene, thus facilitating detection of the labelled product in those cells. In the case of radiotherapy applications, trapping of the product, which is radioactive as a result of the compound being radiolabelled, permits the product to accumulate in those of the cells in which the protein has been expressed by the foreign gene, thus facilitating radiotherapeutic effects directed specifically at those cells. In the case of chemotherapy applications, interaction of the protein with the compound has either a cytotoxic or a cytostatic effect on the cells, which is enhanced if the product is trapped within those of the cells in which the protein has been expressed.
Airway remodeling is a critical factor determining the pathogenesis and treatment sensitivity of severe asthma (SA) or uncontrolled asthma (UA). The activation of epithelial-mesenchymal trophic units (EMTUs) regulated by airway epithelial cells (AECs) has been proven to induce airway remodeling directly. However, the triggers for EMTU activation and the underlying mechanism of airway remodeling are not fully elucidated. Here, we screened the differentially expressed gene cathepsin C (CTSC; also known as dipeptidyl peptidase 1 [DPP-1]) in epithelia of patients with SA and UA using RNA-sequencing data and further verified the increased expression of CTSC in induced sputum of patients with asthma, which was positively correlated with severity and airway remodeling. Moreover, direct instillation of exogenous CTSC induced airway remodeling. Genetic inhibition of CTSC suppressed EMTU activation and airway remodeling in two asthma models with airway remodeling. Mechanistically, increased secretion of CTSC from AECs induced EMTU activation through the p38-mediated pathway, further inducing airway remodeling. Meanwhile, inhibition of CTSC also reduced the infiltration of inflammatory cells and the production of inflammatory factors in the lungs of asthmatic mice. Consequently, targeting CTSC with compound AZD7986 protected against airway inflammation, EMTU activation, and remodeling in the asthma model. Based on the dual effects of CTSC on airway inflammation and remodeling, CTSC is a potential biomarker and therapeutic target for SA or UA.
CAUTION: Certain glass syringes may malfunction, break or clog when connected to some Needleless Luer Access Devices (NLADs). This syringe has a larger internal syringe tip and an external collar (luer collar). The external collar must remain attached to the syringe. Data shows that, the syringe achieves acceptable connection with the following NLADs: BD SmartSite ™, BBraun Ultrasite ™, BD Q-Syte ™, BD MaxPlus ™, and BBraun Safsite ™. Assure that the needle or NLAD is securely attached before beginning the injection. Visually inspect the glass syringe-needle or glass syringe-NLAD connection before and during drug administration.
This is a prospective, multi center, open, randomized, controlled clinical trial. All cervical carcinoma patients who undergo type III hysterectomy in the hospitals involved in this study were recruited. 5-7 days postoperative, those who meet the inclusion criteria and without the exclusion criteria and sign the consent were randomized grouped of intervention and control objective by 1:1. At the same time, according to the research hospital, menopausal status (menopause vs menopause) and surgery approach (laparoscopic vs open)，they were further stratified randomly. Patients in the intervention group received electrical stimulation treatment based on conventional clinical nursing, while patients in control group only receive routine clinical care. Except for the treatment of electrical stimulation, other research procedures is the same in the two groups. The recovery rate of urination function, pelvic floor function and life quality of the two group is compared.
Globally, people are living longer, and many will have multiple, complex chronic diseases. These chronic diseases are often a leading cause of death and disability particularly in emerging developed countries. For these emerging nations, the current trajectory of gradual health system change is likely to lag changing population needs and escalating cost pressures. Consequently, there is a need for a stepwise evolutionary change in the approach to care delivery in these countries. The integrated care (IC) concept describes a collaborative model for organizing healthcare systems, particularly for chronic disease management that pulls together health systems, social science, managerial and patient-centered perspectives. The IC approach could help drive forward efforts to improve population health outcomes, reduce duplication and inefficiency in health care systems, and could be the solution needed by emerging developed countries.
Many researchers propose manipulating microbiota to prevent and treat related diseases. The brain-gut axis is an object that remains the target of modern research, and it is not without reason that many researchers enrich it with microbiota and diet in its name. Numerous connections and mutual correlations have become the basis for seeking answers to many questions related to pathology as well as human physiology. Disorders of this homeostasis as well as dysbiosis itself accompany neurodegenerative diseases such as Alzheimer's and Parkinson's. Heavily dependent on external factors, modulation of the gut microbiome represents an opportunity to advance the treatment of neurodegenerative diseases. Probiotic interventions, synbiotic interventions, or fecal transplantation can undoubtedly support the biotherapeutic process. A special role is played by diet, which provides metabolites that directly affect the body and the microbiota. A holistic view of the human organism is therefore essential.
Patients received no previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Anxiety and depression are two of the most common comorbidities of COPD, which can directly lead to the number of acute exacerbations and hospitalizations of COPD patients and reduce their quality of life. At present, there are many studies on anxiety and depression in stable COPD, but few studies on anxiety and depression in acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients.
OBJECTIVE: We aim to explore the changes of serum metabolomics in AECOPD complicated with anxiety and depression and to provide some clues for further understanding its pathogenesis.
METHODS: This is an observational high-throughput experimental study based on retrospective data extraction. Twenty-one AECOPD with anxiety and depressive patients and 17 healthy controls (HCs) were retrospectively enrolled in the Second Affiliated Hospital of Anhui Medical University. Hamilton anxiety scale (HAMA) and Hamilton depression scale (HAMD) for anxiety and depression were used to assess the patients with AECOPD. Untargeted metabolomics analysis was carried out to investigate different molecules in the serum of all participants. General information of all participants, baseline data and clinical measurement data of AECOPD patients were collected. Statistical analysis and bioinformatics analysis were performed to reveal different metabolites and perturbed metabolic pathways.
RESULTS: A total of 724 metabolites in positive ionization mode and 555 metabolites in negative ionization mode were different in AECOPD patients with anxiety and depression. The 1,279 serum metabolites could be divided into 77 categories. Based on multivariate and univariate analysis, 74 metabolites were detected in positive ionization mode, and 60 metabolites were detected in negative ionization as differential metabolites. The 134 metabolites were enriched in 18 pathways, including biosynthesis of unsaturated fatty acids, aldosterone synthesis and secretion, protein digestion and absorption, ovarian steroidogenesis, long-term depression, retrograde endocannabinoid signaling, and so on.
CONCLUSION: This work highlights the key metabolites and metabolic pathways disturbed in AECOPD patients with anxiety and depression. These findings support the use of metabolomics to understand the pathogenic mechanisms involved in AECOPD patients with anxiety and depression.
This invention concerns a formulation for treating excess weight or localadipose tissue, the process for preparing it and its use. Indeed, obesity isconventionally defined as an excess of fat. The excess of fatty tissue oftenrepresents several hundred calories. It is obviously the result of animbalance in what scientists call the energy balance, too much intake or toolittle energy use. The excess is naturally stored locally. It is significantthat, considering the energy balance, the excess in intake severelyaggravates the latent imbalance, due to a system of slowed energy use. Thatis why the purpose of this invention is to provide a phyto-active formulationthat can, without constraint, naturally reduce the storage of fatty tissueand can also encourage filtration mechanisms on a local level. The envisagedphyto-active formulation in this invention is currently a specific selection.Excess weight is a chronic disease and it will always be necessary to payattention to intolerance....
Studies to date in patients with normal or impaired renal function have not shown any alteration in renal function with propofol injectable emulsion containing 0.005% disodium edetate. In patients at risk for renal impairment, urinalysis and urine sediment should be checked before initiation of sedation and then be monitored on alternate days during sedation. 

Propofol injectable emulsion contains 0.005% disodium edetate. At high doses (2 to 3 grams per day), EDTA has been reported, on rare occasions, to be toxic to the renal tubules. 

The long-term administration of propofol injectable emulsion to patients with renal failure has not been evaluated. 

The pharmacokinetics of propofol do not appear to be different in people with chronic renal impairment compared to adults with normal renal function. The effects of acute renal failure on the pharmacokinetics of propofol have not been studied.
BACKGROUND: Prostate cancer presents with soft tissue progression (STP) is highly aggressive. We analyzed the risk factor for STP in patients with metastatic castration-resistant prostate cancer (mCRPC) who developed abiraterone acetate (AA) resistance.
METHODS: This retrospective study included patients with mCRPC who received AA between February 2018 and July 2022. STP was defined as recurrent lesions in situ, multiple regional lymph node metastases (mLNM), or visceral metastases. Clinical features of patients with STP were analyzed, and risk factors for STP were further investigated.
RESULTS: Sixty-three patients (mean age, 75.0 years; median follow-up time, 22.3 months) were included in this study. Twenty-three patients (36.5%) presented STP during follow up, the overall survival (OS) after STP was 4.6 months. The serum neuron-specific enolase (NSE) were significantly elevated in patients with STP. Biopsies for 8 patients with STP showed neuroendocrine prostate cancer (NEPC, n = 5) was the major pathological types. Further analysis showed that perineural invasion (PNI) in primary tumor were the independent risk factors (HR = 3.145, P = 0.020) for STP, and PNI was related to the aggressiveness of tumor. Patients with PNI showed shorter castration-resistant progression free survival (median, 23.73 months vs. 25.59 months) and STP progression free survival (median, 19.7 months vs. not reached) compared with patients without PNI.
CONCLUSIONS: STP showed extremely poor prognoses in patients with mCRPC after AA resistance, NEPC is the main pathological type of STP, and PNI in primary tumor was an independent risk factor for STP and indicated poor prognosis of prostate cancer.
Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months. Participants' physician receives a letter that describes the educational intervention and encourages them to do a skin examination at next patient visit.
A dispensing system includes a composition that includes one or more of a deodorizing composition, a fragrancing composition, or a cleaning composition. The system includes a container having a body. The composition is disposed within the container, and a pressure within the container is at least 930 kPa. The system further includes an actuator assembly coupled with the container. The actuator assembly includes a housing, an actuator positioned within the housing and comprising a fluid passageway in fluid communication with the composition, and a nozzle insert disposed within the fluid passageway. The nozzle insert defines a nozzle orifice having an orifice diameter of between about 0.335 mm and about 0.385 mm, and the composition comprises a compressed gas and between about 5% and about 10% by volume ethanol.
A chemically synthesised double stranded short interfering nucleic acid (siNA) that directs RNA interference (RNAi)wherein at least 10 % of the internal nucleotide positions on at least one strand comprise modified nucleotides. Preferably the molecule is from 19 to 27 nucleotides in length and may or may not include ribonucleotides. The chemical modifications may be to one or more pyrimidines which are 2'-deoxy-2'-fluro nucleotides or 2'-trifluoromethoyy nucleotides or to one or more purine nucleotides which are 2'-O-methyl or 2' deoxy nucleotides. The molecule may be synthesised as two fragments joined by a linker or as a single molecule comprising both sense and antisense regions. Further modified nucleotides may be incorporated into the molecule in the sense as well as the antisense region. Modified nucleotides at the 3' end are also claimed. Pharmaceutical compositions comprising such molecules are also claimed. In preferred embodiments 20, 30 40 or 50 % of the residues may be modified.
A separate group of patients undergoing surgery lasting more than 60 min operating time, will be consented as well. These patients have Foley catheters in place during the surgery. Five cc's of urine will be collected from the catheter at pre-determined intervals 5, 10, 20, 40 and 60 minutes, aliquoted (2mL) and frozen in liquid nitrogen and later stored in the -80 freezer.
Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen.